• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

0.6401 -0.0309 (-4.61%)
Streaming Delayed Price Updated: 3:59 PM EDT, Aug 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aprea Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
August 12, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
July 30, 2026
From Aprea Therapeutics
Via GlobeNewswire
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies
June 22, 2026
Via Investor Brand Network
Topics Artificial Intelligence
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
June 22, 2026
Via Investor Brand Network
Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher ↗
May 13, 2026
Via Chartmill
News headline image
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
June 01, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 13, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
April 21, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
April 01, 2026
Funding will support ongoing development of APR-1051, including expansion into selected patient populations where WEE1 mechanism is well suited 
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
March 30, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
March 30, 2026
From Aprea Therapeutics
Via GlobeNewswire
Gapping stocks in Monday's session ↗
March 16, 2026
Via Chartmill
News headline image
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
March 16, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial ↗
February 18, 2026
The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level. 
Via Stocktwits
The market is filled with gapping stocks in Wednesday's session. ↗
February 18, 2026
Via Chartmill
News headline image
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
February 18, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 17, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
February 12, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
February 04, 2026
Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051 
From Aprea Therapeutics
Via GlobeNewswire
Let's take a look at the stocks that are in motion in today's session. ↗
January 30, 2026
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity. ↗
January 30, 2026
Via Chartmill
In today's session, these stocks are experiencing unusual volume. ↗
January 30, 2026
Via Chartmill
Top movers analysis in the middle of the day on 2026-01-30: top gainers and losers in today's session. ↗
January 30, 2026
Via Chartmill
What's going on in today's after hours session ↗
January 29, 2026
Via Chartmill
News headline image
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
January 29, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
January 29, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
December 18, 2025
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Game-Changing News: BEAT, APRE, TOON, MNTS, PRSO, PNPNF, SIGL – Stocks Under $1 Look Now
December 10, 2025
Via AB Newswire
News headline image
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
December 09, 2025
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Datavault AI (NASDAQ: DVLT) a Promising FY26 Forward Multiple, Reports +148% Q3, Expands Tokenization Globally – More Similar Stocks Inside.
November 20, 2025
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap